Pazopanib for the first-line treatment of advanced renal cell carcinoma

Renal cell carcinoma (first line metastatic) - pazopanib: review decision - November 2013 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 110 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: review proposal - September 2013 information

TA215 Pazopanib for the first-line treatment of renal cell carcinoma -Appendix A: provisional matrix of stakeholders (PDF 105 KB)

TA215 Pazopanib for the first-line treatment of renal cell carcinoma: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 287 KB)

TA215 Renal cell carcinoma (first line metastatic) - pazopanib: press release information

2011/030 NICE recommends a new treatment for kidney cancer (PDF 82 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: Equality Impact Assessment form (PDF 76 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: final appraisal determination

Renal cell carcinoma (first line metastatic) - pazopanib: final appraisal determination guidance (PDF 250 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: pre-meeting briefing (PDF 317 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: final scope (PDF 54 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: final matrix (PDF 58 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission

Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission - submission (PDF 5.18 MB)

Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission - systematic review (PDF 4.23 MB)

Renal cell carcinoma (first line metastatic) - pazopanib: clarification letters

Renal cell carcinoma (first line metastatic) - pazopanib: clarification letters - NICE request to the manufacturer for clarification on their submission (PDF 241 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: clarification letters - manufacturer's response (PDF 417 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission Addendum

Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission addendum (PDF 1.48 MB)

Renal cell carcinoma (first line metastatic) - pazopanib: Patient Access Scheme Submission (PDF 866 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: clarification letters addendum

Renal cell carcinoma (first line metastatic) - pazopanib: NICE request to the manufacturer for clarification on their submission addendum (PDF 269 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: Manufacturer's response to NICE's request for clarification (PDF 456 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: patient group, professional group and NHS organisation submission

Renal cell carcinoma (first line metastatic) - pazopanib: Royal College of Nursing (PDF 76 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: Royal College of Physicians / NCRI / RCR / ACP / JCCO (joint submission) (PDF 48 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: NHS Waltham Forest (PDF 53 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives

Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives - Dr David Chao (PDF 15 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives - Jacqueline Lowe (PDF 49 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives - Dr Thomas Powles (PDF 80 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives - Bill Savage (PDF 86 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: Evidence Review Group report (PDF 1.96 MB)

Renal cell carcinoma (first line metastatic) - pazopanib: Evidence Review Group report - factual accuracy check (PDF 129 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: pro-forma response (PDF 42 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: final scope (PDF 54 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: Institute's response to consultee and commentator comments on the draft scope (PDF 126 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: Institute's response to consultee and commentator comments on the provisional matrix (PDF 40 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: provisional matrix (PDF 33 KB)

Renal cell carcinoma (first line metastatic) - pazopanib: draft scope (PDF 37 KB)